Kornimate/medical-research-clean huggingface dataset:
a randomized clinical trial of intravenous methylprednisolone with 2 protocols in patients with graves orbitopathy

Conditions: Graves Ophthalmopathy

Summary: intravenous glucocorticoid (ivgc) is an accessible and effective therapy for graves orbitopathy (go); the 4.5-g weekly protocol is well studied, but many details of treatment protocols need to be clarified. the goal of this trial is to compare the efficacy and safety of weekly and daily protocol of ivgc in go. researchers will compare daily protocol to weekly protocol to see if daily protocol works to treat go.

the goal of this trial is to compare the efficacy and safety of weekly and daily protocol of ivgc in go.

Eligibility criteria:
inclusion criteria: 1. age 18-65 years old; 2. diagnosed as thyroid associated ophthalmopathy by using bartley criteria，moderate to severe (eugogo grade), with cas≥3 points; 3. thyroid function normally lasts for more than 2 months, with oral antithyroid drugs or thyroid surgery, or six months after iodine-131 treatment; 4. without receiving immunosuppressive therapy for thyroid eye disease before. exclusion criteria: (1) severe cardiac, liver and renal insufficiency (2) acute or chronic viral hepatitis or tuberculosis (3) optic neuropathy (4) received immunosuppressive and glucocorticoid therapy for any reason within the past 3 months

Keywords: hyperthyroidism graves ophthalmopathy glucocorticoid
evaluation of 89zr-dfo-nimotuzumab for non-invasive imaging of egfr+ cancers by positron emission tomography (pet)

Conditions: Lung Cancer; Colorectal Cancer

Summary: over-expression of epidermal growth factor receptor (egfr) on cells occurs in all aggressive cancers of epithelial origin. existing tests for monitoring egfr expression are invasive and not reliable. there needs to be a better way to measure egfr expression in cancerous tumors to better tailor cancer treatments. this clinical trial aims to demonstrate the feasibility of imaging cancers that express egfr using 89zr-dfo-nimotuzumab and positron emission tomography (pet)/computerized tomography (ct). by non-invasively imaging the status of egfr, 89zr-dfo-nimotuzumab could be used to assist in the identification of patients who are likely to respond to anti-egfr treatments, including nimotuzumab. the hypothesis is that 89zr-dfo-nimotuzumab will accumulate to tumors over-expressing egfr making them visible when imaged with pet/ct. this hypothesis will be tested in this study, along with the optimal imaging time and diagnostic ability.


Eligibility criteria:
inclusion criteria: * male or female between 18 and 80 years old. * egfr-positive cancer defined by a board certified pathologist * primary or metastatic lesion size \>= 1.5 cm as determined by imaging studies (ultrasonography, mammography, ct or mri) or physical examination. * able to give informed consent. * not currently pregnant or nursing: if female subject must be surgically sterile (has had a documented bilateral oophorectomy and/or documented hysterectomy), post-menopausal (cessation of menses for \> 1 year), non-lactating, or of childbearing potential for whom a urine pregnancy test is negative when taken within the 24 h before administration of 89zr-dfo-nimotuzumab. * who performance status of 0 - 2 * patients naïve to anti-egfr antibodies treatment. exclusion criteria: * unable to tolerate 60 min of pet imaging per session.

Keywords: 89zr nimotuzumab lung cancer colorectal cancer egfr pet pet/ct imaging 89zr-dfo-nimotuzumab
genetic study of newly diagnosed central nervous system tumors in young children

Conditions: Central Nervous System Embryonal Neoplasm

Summary: rationale: genetic studies may help in understanding the genetic processes involved in the development of some types of cancer. purpose: genetic study to learn more about genes involved in the development of central nervous system tumors in young children.

objectives: * identify known genes that have significantly different levels of expression, using microarray gene chip analysis, in infants with newly diagnosed metastatic vs non-metastatic embryonal central nervous system tumors. * determine the protein expression of genes identified by microarray analysis that are involved in cellular functions that regulate angiogenesis, invasion, or metastasis in this patient population. * determine the quantity of gene expression of the confirmed translationally expressed genes using semi-quantitative polymerase chain reaction. outline: this is a multicenter study. tumor samples are analyzed using microarray gene chip analysis. differentially expressed genes are evaluated for protein expression by standard immunohistochemistry and/or western blot analysis, and gene expression is further quantified by semi-quantitative polymerase chain reaction. projected accrual: approximately 80-100 patients (20-25 with metastatic disease and 60-75 with non-metastatic disease) will be accrued for this study within 4-5 years.

Eligibility criteria:
disease characteristics: * histologically confirmed, newly diagnosed, primary intracranial embryonal central nervous system tumor * medulloblastoma * primitive neuroectodermal tumor * medulloepithelioma * ependymoblastoma * neuroblastoma * pineoblastoma * atypical teratoid/rhabdoid tumor * intracranial germ cell tumor * choroid plexus carcinoma * m positive ependymoma * potential enrollment on pbtc-001 therapeutic protocol patient characteristics: age: * under 3 performance status: * not specified life expectancy: * not specified hematopoietic: * not specified hepatic: * not specified renal: * not specified prior concurrent therapy: biologic therapy: * not specified chemotherapy: * no prior chemotherapy endocrine therapy: * prior steroids allowed radiotherapy: * no prior radiotherapy surgery: * not specified other: * no concurrent investigational agents

Keywords: childhood central nervous system germ cell tumor childhood choroid plexus tumor untreated childhood supratentorial primitive neuroectodermal tumor untreated childhood medulloblastoma newly diagnosed childhood ependymoma
educational video for genetic testing

Conditions: Genetic Disease; Cancer

Summary: develop and evaluate the acceptability, feasibility, and preliminary efficacy of an informational video on paired tumor/normal testing for children and adolescents with a new diagnosis of cancer, tumors or other diagnosis.

as over 15% of pediatric cancers are associated with a cancer predisposition, it is increasingly becoming standard of care for children with cancer, as well as those with suspected hereditary risk, to be evaluated for germline cancer predisposition. unfortunately, the increase in pediatric genetic testing has exceeded the pace of research establishing best practices to optimize delivery of care for patients undergoing testing and their families. tumor/normal genetic testing (testing of both tumor tissue and a paired normal sample) at time of cancer diagnosis or relapse is now widespread in pediatric oncology to improve cancer diagnostics, prognostics, and treatment; this testing also has potential to uncover underlying cancer predisposition syndromes with lifelong implications. disseminating information at the time of cancer diagnosis is difficult, and is best done by a provider with expertise in cancer genetics. thus, investigators will develop an informational video for use prior to tumor/normal genetic testing to augment genetic counseling resources to support patients and families. in this study, investigators will develop and evaluate the acceptability, feasibility, and preliminary efficacy of an informational video on paired tumor/normal testing for children and adolescents with a new diagnosis of cancer, tumors or other diagnosis. investigators will use a non randomized trial whereby a convenience sample of patients/families will be recruited to be controls in year 1, followed by a convenience sample that will be allocated the video intervention in year 2. to evaluate the impact of the video intervention, investigators will compare assessments of two cohorts- an unexposed (no video intervention, year 1) and exposed (video intervention, year 2).

Eligibility criteria:
inclusion criteria: parents 1. parent or legal guardian of a patient with a new diagnosis of cancer, tumor, or other diagnosis referred for tumor/normal sequencing (proband) in the cancer center at the children's hospital of philadelphia (chop) 2. able to be approached within 1-4 weeks of tumor/normal sequencing 3. appropriate to approach per oncology team 4. no cognitive impairment limiting ability to complete measures 5. ability to read and speak english fluently adolescent/young adult (aya) probands 1. child proband receiving germline testing in the cancer center at chop 2. ages 12+ 3. able to be approached within 1-4 weeks of tumor/normal sequencing 4. appropriate to approach per oncology team 5. no cognitive impairment limiting ability to complete measures 6. ability to read and speak english fluently exclusion criteria: 1) not meeting any of inclusion criteria.

Keywords: genetic testing genetic counseling germline testing educational video
dose-escalation and safety study of apc-100 for the treatment of prostate cancer

Conditions: Prostate Cancer

Summary: this study is a phase 1/2a, open label, dose escalation and safety study of apc-100 (2,2,5,7,8-pentamethyl-6-chromanol) in men with advanced prostate cancer.


Eligibility criteria:
inclusion criteria: * patients with histopathologically proven adenocarcinoma of the prostate * patients must have progressive disease * patients must have had prior treatment with bilateral orchiectomy or androgen deprivation therapy with an lhrh-blocker with evidence of treatment failure exclusion criteria: * patients treated with other secondary hormonal therapies * patients with prior chemotherapy given for castrate-resistant prostate cancer * patients with prior radiation therapy completed less than 4 weeks prior enrollment * patients with prior investigational therapies within 4 weeks before treatment with apc-100 * evidence of active second malignancy
cannabidiol (cbd) for the treatment of social anxiety disorder

Conditions: Social Anxiety Disorder

Summary: a phase 2, multicenter, double-blind, parallel group, placebo-controlled, randomized clinical study, designed to compare the efficacy, safety, and tolerability of 2 dose levels of cbd and a matching placebo for the treatment of subjects with social anxiety disorder (sad).


Eligibility criteria:
inclusion criteria: * clinically predominant diagnosis of diagnostic and statistical manual of mental disorders, fifth edition (dsm-5) sad * lsas score of 70 or higher * females of childbearing potential must test negative for pregnancy and agree to use a reliable birth control method. male subjects must also agree to use highly effective methods of contraception. * read, understand, and sign the informed consent form. * no significant physical health abnormalities based on physical exam, ecg and laboratory tests. exclusion criteria: * other current psychiatric disorder as the clinically predominant diagnosis. * lifetime diagnosis of schizophrenia or any other psychosis, mdd with psychotic features, intellectual disability, autism spectrum disorders, bipolar disorder type 1, and cannabis use disorder * previous 6 months diagnosis of post-traumatic stress disorder, obsessive compulsive disorder, moderate to severe alcohol use disorder, and substance abuse disorder (except tobacco use disorder or mild alcohol use disorder) * severe mdd * use of oral psychoactive medications or beta adrenergic antagonists in the past 4 weeks, or depot neuroleptics within 12 weeks * electroconvulsive therapy within 6 months, psychotherapy or transcranial magnetic stimulation within 3 months * clinically significant abnormality or clinically significant unstable medical condition * impaired liver function * significant risk of suicide or homicide * pregnancy/lactation * sensitivity to cbd or excipients * current cannabis use; past frequent cannabis use * illegal drug use
oscillation and lung expansion therapy in patients with covid-19

Conditions: COVID-19; Oscillation and Lung Expansion

Summary: a pilot study of the use of oscillation and lung expansion (ole) therapy in patients hospitalized with covid-19

this is a randomized prospective open-label cohort study in patients with covid-19 to evaluate the impact of oscillation and lung expansion (ole) therapy using the metaneb® system on the hospital length of stay in patients hospitalized and receiving heated high-flow oxygen therapy for covid-19 infection. the active treatment group will consist of patients who are treated ole therapy while on heated high-flow oxygen therapy . results from subjects in the active treatment group will be compared to results from patients treated with standard care with no ole therapy.

Eligibility criteria:
inclusion criteria: * adult patient (\> 18 years of age) * tested positive or person under investigation (pui) for covid-19 infection * currently require heated high-flow oxygen therapy to maintain sao2 \> 90 % * signed informed consent (phone consent) * heated high-flow oxygen initiated within the past 72 hours exclusion criteria: * serious medical condition that, in the investigator's judgment, precludes the patient's safe participation in the study * pressure related risk for pneumothorax * patient inability or unwillingness to tolerate ole therapy * staff unavailable or unable to deliver therapy * current requirement for mechanical ventilation or expected requirement for mechanical ventilation within the next 12 hours
randomized clinical trial of ceramic bearing primary total hip arthroplasty

Conditions: Total Hip Replacement

Summary: primary total hip arthroplasty (tha) has been a very successful surgical intervention in the geriatric population. numerous studies have reported good mid and long term results of tha in patients over the age of 60 years. with the reported high success rate of this surgical intervention, the tha surgery is being performed in younger patients who have significant joint disease. a clinical trial, using a randomized blinded design, was undertaken to compare the functional outcome of 1) alumina heads/alumina liners, and 2) alumina head/crossfire polyethylene liners in patients 60 years of age or younger with non-inflammatory arthritis of the hip. subjects were assessed preoperatively and at one and five years postoperatively. ten-year follow-up is currently underway. the primary outcome measure is the womac osteoarthritis index. secondary measures were the rand-12, as well as measurement of complication and revision rates. the patient's demand on the implant as calculated by the patient's age, weight, health status and activity level was also measured.


Eligibility criteria:
inclusion criteria: * males or females scheduled for primary tha to treat non-inflammatory arthritis * less than 61 years old at time of surgery * able to speak and read the english language or have an available translator * dorr index a or b bone quality on preoperative radiographs * willing and able to return for follow-up visits exclusion criteria: * have femoral or acetabular bone deficiency requiring augmentation * ongoing corticosteroid use * dorr index c bone quality on the preoperative radiograph * required a prosthesis neck length of greater than five millimeters

Keywords: joint replacement health related quality of life functional outcomes revision rate
fascia iliaca compartment blocks for pain control in hip fractures

Conditions: Hip Fractures

Summary: this study is comparing the use of a peripheral nerve block and standard opioid pain medications in pain control in hip fractures prior to surgery. a peripheral nerve block is a procedure that injects numbing medicine around a nerve to help decrease the pain, motion, and sensation around the painful site temporarily. the purpose of this study is to evaluate if peripheral nerve blocks are more effective for pain control than just standard opioid pain medication while decreasing the amount of side effects from opioid medication.


Eligibility criteria:
inclusion criteria: * aged 50 or older, low energy hip fracture, acute hip fracture exclusion criteria: * on anticoagulants, hardware present near injection site, preexisting nerve injury.
induced sputum study (0000-065)

Conditions: Asthma

Summary: the primary goals of this study will be to implement innovative processing and detection assays to qualify induced sputum measurements of markers of allergen-induced airway inflammation. the results of this study are intended to form a platform to be used in the clinical development of novel asthma therapeutics.


Eligibility criteria:
inclusion criteria: * patient has a history of mild to moderate persistent allergic asthma for at least 6 months with typical symptoms, including cough, wheezing, and shortness of breath, is clinically stable and has no history of recent respiratory tract infection within 3 weeks of the start of the study * patient, aside history of asthma, is judged to be in good health based on medical history, physical examination, vital sign measurements, and laboratory safety tests. * patient is able to perform reproducible pulmonary function test. * patient has an allergic response to house dust mite allergen, demonstrates a positive early and late phase response to an inhaled allergen challenge (as defined by a bronchoconstrictive response) * patient is a nonsmoker for at least 12 months. patients must have less than or equal to 10 pack years of smoking to be included. (10 pack years = one pack per day for 10 years.) patients who have discontinued smoking for at least 10 months may be enrolled at the discretion of the investigator * patient is willing to avoid strenuous physical activity (i.e., strenuous or unaccustomed weight lifting, running, bicycling, etc.) for 72 hours prior to each visit when laboratory safety tests are obtained and 48 hours prior to allergen challenge exclusion criteria: * patient has a history of any illness that, in the opinion of the study investigator, might confound the results of the study or poses additional risk to the patient by their participation in the study * patient has taken oral corticosteroids within 8 weeks or inhaled corticosteroids/nasal corticosteroids within 4 weeks of screening and/or during the study * patient has a history of stroke, chronic seizures, or major neurological disorder * patient has a history of clinically significant endocrine, gastrointestinal, cardiovascular, hematological, hepatic, immunological, renal, respiratory (other than asthma), or genitourinary abnormalities or diseases, or has a history of neoplastic disease * patient is unable to refrain from or anticipates the use of any medication other than the ones permitted in this study, including prescription and non-prescription drugs or herbal remedies prior to administration of the initial dose of study drug, throughout the study (including washout intervals between treatment periods), until the poststudy visit * patient consumes excessive amounts of alcohol, defined as greater than 3 glasses of alcoholic beverages per day or \>21 drink equivalents per week. * patient consumes excessive amounts, defined as greater than 6 servings of coffee, tea, cola, or other caffeinated beverages per day
anemia and inflammation

Conditions: Iron Deficiency Anemia; Inflammation

Summary: during inflammation hepcidin concentrations are increased, leading to a decrease in iron absorption. in iron deficiency anemia hepcidin is suppressed due to the activation of erythropoiesis. whether inflammation or anemia has the stronger effect on hepcidin is uncertain.


Eligibility criteria:
inclusion criteria: * bmi \<27.5kg/m2 * body weight \<70kg * either non-anemic (hb\>12.5g/dl) or anemic (hb between 8-12 g/dl and ferritin \<15ng/ml) exclusion criteria: * pregnant or lactating * chronic disease * smoking * inflammation defined as crp\<5mg/l; agp\<1g/l
effective management of calcific aortic stenosis in the elderly

Conditions: Calcific Aortic Stenosis

Summary: although aortic valve replacement is recommended for any symptomatic severe calcific aortic stenosis, the therapeutic decision may be difficult. because of patient age and comorbidities. transcatheter aortic valve implantation (tavi) has recently extended the therapeutic indications in patients at high risk of surgery. however, the proportion of different treatments is not known in a contemporary population that can be treated according to the different resources currently available. the scientific goal of this observational research is to evaluate intra-hospital therapeutic decision in elderly patients referred because of symptomatic severe aortic stenosis. the one-year survival will be analyzed according to the therapeutic decision and the characteristics of the patients.


Eligibility criteria:
inclusion criteria: * hospitalized due to symptomatic tight aortic stenosis (nyha \>= ii, dyspnea, angina or syncope); * having given his consent to participate in the study. exclusion criteria: * non-severe aortic stenosis; * asymptomatic aortic stenosis; * patient under the age of 75; * patient refusing to participate in the study.
effect of statin preloading in stemi in improving pci outcomes

Conditions: ST Elevation Myocardial Infarction

Summary: to compare the effect of a single high dose of atorvastatin versus rosuvastatin preloading on microvascular coronary perfusion as determined by ctfc in patients with st-segment elevation myocardial infarction (stemi) undergoing pci.

acute myocardial infarction (mi) indicates irreversible myocardial injury resulting in necrosis of a significant portion of myocardium which is caused mostly by coronary plaque rupture or erosion. it could result in several clinical complications and impact cardiac prognosis . worldwide, ischemic heart disease is the single most common cause of death and its frequency is increasing, now accounts for almost 1.8 million annual deaths. cholesterol reduction with hmg-coa (3-hydroxy-3-methylglutaryl coenzyme a) reductase inhibitors or statins has been shown to improve mortality and cardiovascular morbidity in patients with established coronary artery disease (cad). previous evidence suggests that statins have various favorable effects on vascular system that are not directly related to their impact on lipid metabolism. beyond lowering lipids, statins have favorable effects on platelet adhesion, thrombosis, endothelial function, plaque stability, and inflammation. . as with acs, the vascular injury from coronary angioplasty and stent placement induces platelet activation, thrombosis, and inflammation within the vessel wall and the distal microvasculature. therefore, in addition to a long-term benefit associated with lipid lowering, statin therapy might play a beneficial role early after pci. conventional timi flow grading (thrombolysis in myocardial infarction) is a predictor of cardiac outcome after acute myocardial infarction and pci, but it has several limitations. the ctfc (corrected timi frame count) another approach to grade flow impairment, is an objective, quantitative, reproducible, and sensitive index for coronary blood flow\[9\]. timi flow may appear normal visually, but may correlate to abnormal ctfc. the ctfc has been proposed to have incremental prognostic accuracy in predicting survival outcome with reperfusion therapy . higher ctfc values after pci have also been found to be associated with poor clinical outcomes.

Eligibility criteria:
inclusion criteria: * the presence of symptoms (\<12h). * st-segment elevation of at least 0.1mv in two contiguous leads of electrocardiogram or new onset left bundle branch block. * patients age 18 to 80 years. exclusion criteria: * previous (within 3 months) or current treatment with statins. * known allergy to heparin, aspirin, clopidogrel, or abciximab. * active severe bleeding. * pregnancy. * history of major surgery or trauma. * significant gastrointestinal or genitourinary bleeding (\<6 weeks). * history of cerebrovascular attack (within 2 years) or cerebrovascular attack with a significant residual neurological deficit. * cardiogenic shock with mechanical ventilation.

Keywords: stemi statin pci